




Searching News Database: Ph+ CML
HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
HSMN NewsFeed - 10 Apr 2006
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer
Additional items found! 5

Members Archive contains
5 additional stories matching:
Ph+ CML
(Password required)
Ph+ CML
(Password required)